CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Matthew J Rendo,Jacinth J Joseph,Liem Minh Phan,Christin B DeStefano
DOI: https://doi.org/10.2147/BLCTT.S327016
2022-08-29
Blood and Lymphatic Cancer: Targets and Therapy
Abstract:Matthew J Rendo, 1 Jacinth J Joseph, 2 Liem Minh Phan, 3 Christin B DeStefano 4 1 Department of Hematology/Oncology, Brooke Army Medical Center, San Antonio, TX, USA; 2 Blood and Marrow Transplant Center, Methodist Le Bonheur Healthcare, Memphis, TN, USA; 3 Clinical Investigation Facility, David Grant USAF Medical Center, Travis Air Force Base, CA, USA; 4 Department of Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, MD, USA Correspondence: Christin B DeStefano, Email The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges. Keywords: multiple myeloma, CAR T-cell, immunotherapy Multiple myeloma (MM) is the second most common hematologic malignancy diagnosed in the United States (U.S.). 1 Although relapses are frequent, novel therapies have improved long-term outcomes as a median survival of over 10 years has been observed. 2 Chimeric antigen receptor (CAR) T-cells have recently gained US Food and Drug Administration (FDA) approval for use in MM. CAR T-cells serve as a promising therapy in the treatment landscape of MM given their unprecedented responses in a refractory population, yet their logistical and clinical limitations must be acknowledged to further improve patient outcomes. Genetically engineered T-cells were initially studied in 1989 to exploit cytotoxic T-cell effector functions. 3 Cytotoxic T-cells can induce targeted cell killing through expression of FasL, release of granzyme, perforin, and pro-inflammatory cytokines, all of which activate target cell mitochondrial caspases and trigger apoptosis. 4 T-cell activation requires binding of a T-cell receptor to its cognate antigen and class 1 major histocompatibility complex (MHC) as well as binding of a T-cell costimulatory receptor to its ligand. 5 Once the T-cell receptor and its costimulatory receptor bind their targets, the T-cell receptor cytoplasmic domain (CD3ζ) triggers intracellular signaling pathways, inducing T-cell activation and robust cell-kill (Figure 1). CAR T-cells possess the lethal functions of cytotoxic T-cells but are engineered to be highly specific to their target antigen(s) and do not require MHC or costimulatory binding. 6 Current FDA approved CAR T-cells for hematologic malignancies are second-generation CAR T-cells, composed of a single chain variable fragment (scFv) extracellular domain, a transmembrane domain (CD3ζ), and an intracytoplasmic T-cell costimulatory domain (Figure 2). 6,7 After infusion, CAR T-cells bind their target antigen(s), proliferate, release tumor antigens, induce epitope spreading, and recruit other immune cells, ultimately orchestrating a multi-faceted immune response resulting in robust cell kill. 6,8 Figure 1 Cytotoxic T-cell. Figure 2 2nd Generation CAR T-cell Structure. Autologous CAR T-cell treatment requires leukapheresis of host T-cells followed by CAR T-cell manufacturing, bridging therapy if needed for disease control during manufacturing, administration of lymphodepleting drugs, and CAR T-cell infusion (Figure 3). Although hospitalization is standard after infusion, outpatient CAR T-cells are being delivered at select centers in highly selected patients. CAR T-cell manufacturing may take up to 6 weeks. During this time, ex-vivo T-cell stimulation and expansion occur. Isolated T-cells are stimulated to proliferate and expand via exposure to various pro-growth cytokines to include anti-CD3 antibodies and interleukin (IL)-2. 9 Afterward, a lentiviral or gamma retroviral vector is used to transfer the gene encoding the CAR product into the T-cell genome. 10 Of note, gene transfer can occur through other mechanisms as described in Investigational CAR T-Cell Therapies. Figure 3 Autologous CAR T-cell Process. The first B-cell maturation antigen (BCMA)-targeting CAR T-cells were studied in MM in 2013. 11 The target antigen, BCMA, is a tumor necrosis factor receptor (TNFR) superfamily member 17 surface protein found predominantly on plasma cells. 11 Overexpression of BCMA b -Abstract Truncated-